peginterferon alfa-2a + ribavirin + pioglitazone

This is a combination regimen of three drugs: **peginterferon alfa-2a**, **ribavirin**, and **pioglitazone**. Peginterferon alfa-2a is a pegylated interferon used as an immunomodulatory and antiviral agent; it binds to cell surface receptors and induces antiviral, antiproliferative, and immunomodulating activities. Ribavirin is a nucleoside analog with antiviral activity, often used in combination with interferons for the treatment of chronic hepatitis C. Pioglitazone is a thiazolidinedione that acts as an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving insulin sensitivity. This triple regimen has been studied in patients with chronic hepatitis C and insulin resistance, hypothesizing that pioglitazone’s improvement of insulin sensitivity may increase the likelihood of virological response to standard antiviral therapy[1][3]. The combination is experimental and is not an approved fixed-dose combination product; it has mainly been evaluated in investigator-initiated or pilot clinical trials.